HUC-3443 by Huons for Idiopathic (Essential) Hypertension: Likelihood of Approval

HUC-3443 is under clinical development by Huons and currently in Phase II for Idiopathic (Essential) Hypertension.

Vitamin D-MS Link; Nootropic Gummies Laced With Psilocybin; Forecasting Seizures

Vitamin D levels before starting treatment were tied to subsequent multiple sclerosis (MS) disease activity. (Journal of Neurology, Neurosurgery, and Psychiatry) Several brands of nootropic

July 24, 2024

Star power eclipses science in obesity discussions on social media

Celebrity tweets about obesity and weight loss attract far more positive engagement than those from medical authorities, underscoring their potential as powerful health messengers.

December 2, 2024

Theseus goes back to preclinical mode after axing lead targeted therapy over tolerability concerns, shares plummet

Theseus Pharmaceuticals has run into dose-limiting toxicities that’s forcing the company to abandon its KIT inhibitor, two months after presenting initial data on the program

July 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.